Ingredient or product comparison
GHK-Cu for Arthritis Research: Comparison
GHK-Cu TGF-beta signalling activation, NF-kB inhibition, copper cofactor delivery Yes. MMP-1/3 reduced 55–60% Yes. COL1A1/COL3A1 upregulated 50–70% TNF-alpha reduced 52%, IL-6 reduced 48% Dual-action compound addressing both degradation and repair. Rare in art
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu
- TGF-beta signalling activation, NF-kB inhibition, copper cofactor delivery
- Yes. MMP-1/3 reduced 55–60%
- Yes. COL1A1/COL3A1 upregulated 50–70%
- TNF-alpha reduced 52%, IL-6 reduced 48%
- Dual-action compound addressing both degradation and repair. Rare in arthritis research compounds
- NSAIDs (e.g., ibuprofen)
- COX-1/COX-2 enzyme inhibition
- No direct effect
- No. May inhibit repair
- Reduces prostaglandin-mediated pain signals
- Symptom management only. No disease-modifying effect on cartilage structure
- Corticosteroids (e.g., prednisone)
- Glucocorticoid receptor activation, broad immune suppression
- Yes. But non-selective
- No. Actively inhibits collagen synthesis long-term
- Broad suppression of cytokine transcription
- Powerful anti-inflammatory but worsens cartilage health with chronic use
- Hyaluronic acid injections
- Viscosupplementation, mechanical cushioning
- No
- Minimal. Acts as physical barrier
- Provides temporary symptom relief without modifying underlying pathology
- Glucosamine/chondroitin
- Substrate provision for proteoglycan synthesis
- Minimal. Low bioavailability
- No significant anti-inflammatory effect
- Limited evidence for structural benefit; effect size smaller than GHK-Cu in comparable models
- BPC-157
- VEGF upregulation, fibroblast migration
- Yes. Angiogenesis-dependent
- Yes. Indirect via growth factor signalling
- Moderate. Primarily through tissue oxygenation
- Angiogenic focus makes it complementary to GHK-Cu for joint repair research